Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance

Trastuzumab, a targeted anti-human epidermal-growth-factor receptor-2 (HER2) monoclonal antibody, represents a mainstay in the treatment of HER2-positive (HER2(+)) breast cancer. Although trastuzumab treatment is highly efficacious for early-stage HER2(+) breast cancer, the majority of advanced-stag...

Descripción completa

Detalles Bibliográficos
Autores principales: Upton, Rosalynd, Banuelos, Allison, Feng, Dongdong, Biswas, Tanuka, Kao, Kevin, McKenna, Kelly, Willingham, Stephen, Ho, Po Yi, Rosental, Benyamin, Tal, Michal Caspi, Raveh, Tal, Volkmer, Jens-Peter, Pegram, Mark D., Weissman, Irving L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: National Academy of Sciences 2021
Materias:
Biological Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8307693/
https://www.ncbi.nlm.nih.gov/pubmed/34257155
http://dx.doi.org/10.1073/pnas.2026849118

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8307693/
https://www.ncbi.nlm.nih.gov/pubmed/34257155
http://dx.doi.org/10.1073/pnas.2026849118

Ejemplares similares